Close
  Indian J Med Microbiol
 

Figure 15: Comparison of IL-23 blockers from different trials at week 28/week 24/week 44—tildrakizumab (reSURFACE 2) at week 28; guselkumab (VOYAGE 1) at week 24; and risankizumab (PASI 75/PASI 90 data from phase 2 trial at week 24 and PASI 100 data at week 44 from IMMvent trial)

Figure 15: Comparison of IL-23 blockers from different trials at week 28/week 24/week 44—tildrakizumab (reSURFACE 2) at week 28; guselkumab (VOYAGE 1) at week 24; and risankizumab (PASI 75/PASI 90 data from phase 2 trial at week 24 and PASI 100 data at week 44 from IMMvent trial)